{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T22:06:11Z","timestamp":1766181971381},"reference-count":95,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T00:00:00Z","timestamp":1668211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T00:00:00Z","timestamp":1668211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Endocr Disord"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The interplay between HCV, DM, and DAA therapy is poorly understood. We compared HCV infection characteristics, treatment uptake, and treatment outcomes in patients with and without DM.\u00a0<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A retrospective cohort study was conducted using data from The Ottawa Hospital Viral Hepatitis Program. Statistical comparisons between diabetes and non-diabetes were made using \u03c7<jats:sup>2<\/jats:sup> and t-tests. Logistic regression analyses were performed to assess predictors of DM and SVR.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>One thousand five hundred eighty-eight HCV patients were included in this analysis; 9.6% had DM. Patients with DM were older and more likely to have cirrhosis. HCC and chronic renal disease were more prevalent in the DM group. Treatment uptake and SVR were comparable between groups. Regression analysis revealed that age and employment were associated with achieving SVR. Post-SVR HCC was higher in DM group.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>The high prevalence of DM in our HCV cohort supports screening. Further assessment is required to determine if targeted, early DAA treatment reduces DM onset, progression to cirrhosis and HCC risk. Further studies are needed to determine if optimization of glycemic control in this population can lead to improved liver outcomes.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12902-022-01198-x","type":"journal-article","created":{"date-parts":[[2022,11,12]],"date-time":"2022-11-12T07:04:04Z","timestamp":1668236644000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["HCV infection characteristics, treatment uptake and outcomes in patient with diabetes mellitus"],"prefix":"10.1186","volume":"22","author":[{"given":"Marina","family":"Angel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yelena","family":"Petrosyan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary-Anne","family":"Doyle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Curtis","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,11,12]]},"reference":[{"issue":"3","key":"1198_CR1","first-page":"274","volume":"34","author":"HM Diaz","year":"2019","unstructured":"Diaz HM, Mindiola AL, Aldana AG. Pathophysiology of hepatitis C and diabetes mellitus: Towards the cure of two epidemics in the 21st century. Revista Colombiana de Gastroenterologia. 2019;34(3):274\u201383.","journal-title":"Revista Colombiana de Gastroenterologia"},{"issue":"10","key":"1198_CR2","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.cmi.2016.07.035","volume":"22","author":"S Lanini","year":"2016","unstructured":"Lanini S, Easterbrook PJ, Zumla A, Ippolito G. Hepatitis C: global epidemiology and strategies for control. Clin Microbiol Infect. 2016;22(10):833\u20138.","journal-title":"Clin Microbiol Infect"},{"key":"1198_CR3","doi-asserted-by":"publisher","first-page":"107843","DOI":"10.1016\/j.diabres.2019.107843","volume":"157","author":"P Saeedi","year":"2019","unstructured":"Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N, Colagiuri S, Guariguata L, Motala AA, Ogurtsova K, et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9(th) edition. Diabetes Res Clin Pract. 2019;157:107843.","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"1198_CR4","doi-asserted-by":"publisher","first-page":"52","DOI":"10.4239\/wjd.v5.i1.52","volume":"5","author":"SK Bose","year":"2014","unstructured":"Bose SK, Ray R. Hepatitis C virus infection and insulin resistance. World J Diabetes. 2014;5(1):52\u20138.","journal-title":"World J Diabetes"},{"key":"1198_CR5","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3389\/fendo.2015.00134","volume":"6","author":"SS Hammerstad","year":"2015","unstructured":"Hammerstad SS, Grock SF, Lee HJ, Hasham A, Sundaram N, Tomer Y. Diabetes and Hepatitis C: A Two-Way Association. Front Endocrinol (Lausanne). 2015;6:134.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"1198_CR6","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/j.1872-034X.2007.00052.x","volume":"37","author":"I Konishi","year":"2007","unstructured":"Konishi I, Horiike N, Hiasa Y, Tokumoto Y, Mashiba T, Michitaka K, Miyake Y, Nonaka S, Joukou K, Matsuura B, et al. Diabetes mellitus reduces the therapeutic effectiveness of interferon-alpha2b plus ribavirin therapy in patients with chronic hepatitis C. Hepatol Res. 2007;37(5):331\u20136.","journal-title":"Hepatol Res"},{"issue":"6","key":"1198_CR7","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1056\/NEJMoa0808010","volume":"361","author":"JG McHutchison","year":"2009","unstructured":"McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, Nyberg LM, Lee WM, Ghalib RH, Schiff ER, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009;361(6):580\u201393.","journal-title":"N Engl J Med"},{"issue":"3","key":"1198_CR8","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1053\/j.gastro.2004.12.049","volume":"128","author":"M Romero-Gomez","year":"2005","unstructured":"Romero-Gomez M, Del Mar Viloria M, Andrade RJ, Salmeron J, Diago M, Fernandez-Rodriguez CM, Corpas R, Cruz M, Grande L, Vazquez L, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology. 2005;128(3):636\u201341.","journal-title":"Gastroenterology"},{"issue":"3","key":"1198_CR9","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3748\/wjg.v18.i3.212","volume":"18","author":"AR El-Zayadi","year":"2012","unstructured":"El-Zayadi AR, Anis M. Hepatitis C virus induced insulin resistance impairs response to anti viral therapy. World J Gastroenterol. 2012;18(3):212\u201324.","journal-title":"World J Gastroenterol"},{"issue":"2","key":"1198_CR10","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1093\/rheumatology\/keh011","volume":"43","author":"A Antonelli","year":"2004","unstructured":"Antonelli A, Ferri C, Fallahi P, Sebastiani M, Nesti C, Barani L, Barale R, Ferrannini E. Type 2 diabetes in hepatitis C-related mixed cryoglobulinaemia patients. Rheumatology (Oxford). 2004;43(2):238\u201340.","journal-title":"Rheumatology (Oxford)"},{"key":"1198_CR11","first-page":"48","volume-title":"Update on Hepatitis C","author":"I Bili\u0107-\u0106ur\u010di\u0107","year":"2017","unstructured":"Bili\u0107-\u0106ur\u010di\u0107 I, Rogulji\u0107 H, Ivandi\u0107 M, V\u010dev A, Smoli\u0107 R, Smoli\u0107 M. Hepatitis C-Associated Diabetes Mellitus. In: Smolic M, Vcev A, editors. Update on Hepatitis C. Wu G: IntechOpen; 2017. p. 48\u201355."},{"key":"1198_CR12","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1186\/1743-422X-7-304","volume":"7","author":"NA Jadoon","year":"2010","unstructured":"Jadoon NA, Shahzad MA, Yaqoob R, Hussain M, Ali N. Seroprevalence of hepatitis C in type 2 diabetes: evidence for a positive association. Virol J. 2010;7:304.","journal-title":"Virol J"},{"issue":"5","key":"1198_CR13","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.2337\/dc05-1995","volume":"29","author":"A Lecube","year":"2006","unstructured":"Lecube A, Hernandez C, Genesca J, Simo R. Glucose abnormalities in patients with hepatitis C virus infection: Epidemiology and pathogenesis. Diabetes Care. 2006;29(5):1140\u20139.","journal-title":"Diabetes Care"},{"issue":"2","key":"1198_CR14","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1002\/hep.510290235","volume":"29","author":"AL Mason","year":"1999","unstructured":"Mason AL, Lau JY, Hoang N, Qian K, Alexander GJ, Xu L, Guo L, Jacob S, Regenstein FG, Zimmerman R, et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology. 1999;29(2):328\u201333.","journal-title":"Hepatology"},{"issue":"10","key":"1198_CR15","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1111\/j.1478-3231.2009.02095.x","volume":"29","author":"AJ Montano-Loza","year":"2009","unstructured":"Montano-Loza AJ, Sultan A, Falanga D, Loss G, Mason AL. Immunogenetic susceptibility to diabetes mellitus in patients with liver disease. Liver Int. 2009;29(10):1543\u201351.","journal-title":"Liver Int"},{"issue":"5","key":"1198_CR16","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.jhep.2008.08.006","volume":"49","author":"DL White","year":"2008","unstructured":"White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: a systematic review and meta-analysis. J Hepatol. 2008;49(5):831\u201344.","journal-title":"J Hepatol"},{"issue":"5","key":"1198_CR17","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1016\/S0002-9440(10)63408-6","volume":"165","author":"T Kawaguchi","year":"2004","unstructured":"Kawaguchi T, Yoshida T, Harada M, Hisamoto T, Nagao Y, Ide T, Taniguchi E, Kumemura H, Hanada S, Maeyama M, et al. Hepatitis C virus down-regulates insulin receptor substrates 1 and 2 through up-regulation of suppressor of cytokine signaling 3. Am J Pathol. 2004;165(5):1499\u2013508.","journal-title":"Am J Pathol"},{"issue":"1 Suppl","key":"1198_CR18","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.1016\/j.jhep.2014.08.003","volume":"61","author":"F Negro","year":"2014","unstructured":"Negro F. Facts and fictions of HCV and comorbidities: steatosis, diabetes mellitus, and cardiovascular diseases. J Hepatol. 2014;61(1 Suppl):S69-78.","journal-title":"J Hepatol"},{"issue":"Pt 7","key":"1198_CR19","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1099\/vir.0.020644-0","volume":"91","author":"V Pazienza","year":"2010","unstructured":"Pazienza V, Vinciguerra M, Andriulli A, Mangia A. Hepatitis C virus core protein genotype 3a increases SOCS-7 expression through PPAR-{gamma} in Huh-7 cells. J Gen Virol. 2010;91(Pt 7):1678\u201386.","journal-title":"J Gen Virol"},{"issue":"10","key":"1198_CR20","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1515\/CCLM.2009.280","volume":"47","author":"M Persico","year":"2009","unstructured":"Persico M, Russo R, Persico E, Svelto M, Spano D, Andolfo I, La Mura V, Capasso M, Tiribelli C, Torella R, et al. SOCS3 and IRS-1 gene expression differs between genotype 1 and genotype 2 hepatitis C virus-infected HepG2 cells. Clin Chem Lab Med. 2009;47(10):1217\u201325.","journal-title":"Clin Chem Lab Med"},{"issue":"3","key":"1198_CR21","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.cld.2017.03.004","volume":"21","author":"L Serfaty","year":"2017","unstructured":"Serfaty L. Metabolic Manifestations of Hepatitis C Virus: Diabetes Mellitus, Dyslipidemia. Clin Liver Dis. 2017;21(3):475\u201386.","journal-title":"Clin Liver Dis"},{"issue":"6","key":"1198_CR22","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1016\/j.hep.2003.09.012","volume":"38","author":"S Aytug","year":"2003","unstructured":"Aytug S, Reich D, Sapiro LE, Bernstein D, Begum N. Impaired IRS-1\/PI3-kinase signaling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes. Hepatology. 2003;38(6):1384\u201392.","journal-title":"Hepatology"},{"issue":"2","key":"1198_CR23","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/j.1440-1746.2007.05183.x","volume":"23","author":"M Itou","year":"2008","unstructured":"Itou M, Kawaguchi T, Taniguchi E, Sumie S, Oriishi T, Mitsuyama K, Tsuruta O, Ueno T, Sata M. Altered expression of glucagon-like peptide-1 and dipeptidyl peptidase IV in patients with HCV-related glucose intolerance. J Gastroenterol Hepatol. 2008;23(2):244\u201351.","journal-title":"J Gastroenterol Hepatol"},{"issue":"12","key":"1198_CR24","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1111\/j.1572-0241.2003.08728.x","volume":"98","author":"H Knobler","year":"2003","unstructured":"Knobler H, Zhornicky T, Sandler A, Haran N, Ashur Y, Schattner A. Tumor necrosis factor-alpha-induced insulin resistance may mediate the hepatitis C virus-diabetes association. Am J Gastroenterol. 2003;98(12):2751\u20136.","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"1198_CR25","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.2337\/dc05-2509","volume":"29","author":"A Lecube","year":"2006","unstructured":"Lecube A, Hernandez C, Genesca J, Simo R. Proinflammatory cytokines, insulin resistance, and insulin secretion in chronic hepatitis C patients: A case-control study. Diabetes Care. 2006;29(5):1096\u2013101.","journal-title":"Diabetes Care"},{"issue":"4","key":"1198_CR26","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1111\/j.1872-034X.2007.00280.x","volume":"38","author":"H Mitsuyoshi","year":"2008","unstructured":"Mitsuyoshi H, Itoh Y, Sumida Y, Minami M, Yasui K, Nakashima T, Okanoue T. Evidence of oxidative stress as a cofactor in the development of insulin resistance in patients with chronic hepatitis C. Hepatol Res. 2008;38(4):348\u201353.","journal-title":"Hepatol Res"},{"issue":"4","key":"1198_CR27","doi-asserted-by":"publisher","first-page":"940","DOI":"10.2337\/diacare.28.4.940","volume":"28","author":"M Masini","year":"2005","unstructured":"Masini M, Campani D, Boggi U, Menicagli M, Funel N, Pollera M, Lupi R, Del Guerra S, Bugliani M, Torri S, et al. Hepatitis C virus infection and human pancreatic beta-cell dysfunction. Diabetes Care. 2005;28(4):940\u20131.","journal-title":"Diabetes Care"},{"issue":"6","key":"1198_CR28","doi-asserted-by":"publisher","first-page":"e38522","DOI":"10.1371\/journal.pone.0038522","volume":"7","author":"Q Wang","year":"2012","unstructured":"Wang Q, Chen J, Wang Y, Han X, Chen X. Hepatitis C virus induced a novel apoptosis-like death of pancreatic beta cells through a caspase 3-dependent pathway. PLoS One. 2012;7(6):e38522.","journal-title":"PLoS One"},{"key":"1198_CR29","doi-asserted-by":"crossref","unstructured":"El Badry M, Ali D, Eltaweel N, Abdel-Wahed M. Effect of eradication of HCV infection by direct-acting antivirals in diabetic HCV-infected patients as regards glycemic control. Egyptian Liver J. 2020;10(54):1\u20137.","DOI":"10.1186\/s43066-020-00061-9"},{"issue":"9","key":"1198_CR30","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.2337\/dc17-0485","volume":"40","author":"J Hum","year":"2017","unstructured":"Hum J, Jou JH, Green PK, Berry K, Lundblad J, Hettinger BD, Chang M, Ioannou GN. Improvement in Glycemic Control of Type 2 Diabetes After Successful Treatment of Hepatitis C Virus. Diabetes Care. 2017;40(9):1173\u201380.","journal-title":"Diabetes Care"},{"key":"1198_CR31","doi-asserted-by":"publisher","first-page":"7807921","DOI":"10.1155\/2016\/7807921","volume":"2016","author":"RA Pashun","year":"2016","unstructured":"Pashun RA, Shen NT, Jesudian A. Markedly Improved Glycemic Control in Poorly Controlled Type 2 Diabetes following Direct Acting Antiviral Treatment of Genotype 1 Hepatitis C. Case Reports Hepatol. 2016;2016:7807921.","journal-title":"Case Reports Hepatol"},{"issue":"5","key":"1198_CR32","doi-asserted-by":"publisher","first-page":"462 e461","DOI":"10.1016\/j.cmi.2015.12.030","volume":"22","author":"P Pavone","year":"2016","unstructured":"Pavone P, Tieghi T, d\u2019Ettorre G, Lichtner M, Marocco R, Mezzaroma I, Passavanti G, Vittozzi P, Mastroianni CM, Vullo V. Rapid decline of fasting glucose in HCV diabetic patients treated with direct-acting antiviral agents. Clin Microbiol Infect. 2016;22(5):462 e461-463.","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"1198_CR33","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.cmi.2016.09.021","volume":"23","author":"C Fabrizio","year":"2017","unstructured":"Fabrizio C, Procopio A, Scudeller L, Dell\u2019Acqua R, Bruno G, Milano E, Milella M, Saracino A, Angarano G. HCV and diabetes: towards a \u201csustained\u201d glycaemic improvement after treatment with DAAs? Clin Microbiol Infect. 2017;23(5):342\u20133.","journal-title":"Clin Microbiol Infect"},{"issue":"7","key":"1198_CR34","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1111\/jgh.14067","volume":"33","author":"LE Adinolfi","year":"2018","unstructured":"Adinolfi LE, Nevola R, Guerrera B, D\u2019Alterio G, Marrone A, Giordano M, Rinaldi L. Hepatitis C virus clearance by direct-acting antiviral treatments and impact on insulin resistance in chronic hepatitis C patients. J Gastroenterol Hepatol. 2018;33(7):1379\u201382.","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"1198_CR35","doi-asserted-by":"publisher","first-page":"187","DOI":"10.4103\/AZMJ.AZMJ_7_18","volume":"15","author":"A Hashim","year":"2017","unstructured":"Hashim A, Kandeel H, El-Mola K, El-Raey F, Attia M. Effect of new direct-acting antiviral drugs on insulin resistance and glycemic control after treatment of chronic hepatitis C virus infection in type 2 diabetic patients. Al-Azhar Assiut Medical Journal. 2017;15(4):187\u201395.","journal-title":"Al-Azhar Assiut Medical Journal"},{"issue":"3","key":"1198_CR36","doi-asserted-by":"publisher","first-page":"281","DOI":"10.15403\/jgld.2014.1121.273.daa","volume":"27","author":"P Weidner","year":"2018","unstructured":"Weidner P, Boettche D, Zimmerer T, Burgermeister E, Teufel A, Ebert MPA, Antoni C. Impact of direct acting antiviral (DAA) treatment on glucose metabolism and reduction of pre-diabetes in patients with chronic hepatitis C. J Gastrointestin Liver Dis. 2018;27(3):281\u20139.","journal-title":"J Gastrointestin Liver Dis"},{"issue":"2","key":"1198_CR37","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/nm1166","volume":"11","author":"D Cai","year":"2005","unstructured":"Cai D, Yuan M, Frantz DF, Melendez PA, Hansen L, Lee J, Shoelson SE. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med. 2005;11(2):183\u201390.","journal-title":"Nat Med"},{"issue":"3","key":"1198_CR38","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1111\/j.1572-0241.2006.01038.x","volume":"102","author":"T Kawaguchi","year":"2007","unstructured":"Kawaguchi T, Ide T, Taniguchi E, Hirano E, Itou M, Sumie S, Nagao Y, Yanagimoto C, Hanada S, Koga H, et al. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol. 2007;102(3):570\u20136.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"1198_CR39","first-page":"289","volume":"24","author":"P Bedossa","year":"1996","unstructured":"Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group Hepatology. 1996;24(2):289\u201393.","journal-title":"The METAVIR Cooperative Study Group. Hepatology"},{"issue":"6","key":"1198_CR40","doi-asserted-by":"publisher","first-page":"902","DOI":"10.1111\/j.1478-3231.2012.02781.x","volume":"32","author":"RP Myers","year":"2012","unstructured":"Myers RP, Pollett A, Kirsch R, Pomier-Layrargues G, Beaton M, Levstik M, Duarte-Rojo A, Wong D, Crotty P, Elkashab M. Controlled Attenuation Parameter (CAP): a noninvasive method for the detection of hepatic steatosis based on transient elastography. Liver Int. 2012;32(6):902\u201310.","journal-title":"Liver Int"},{"issue":"1","key":"1198_CR41","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1053\/jhep.2000.8270","volume":"32","author":"DL Bigam","year":"2000","unstructured":"Bigam DL, Pennington JJ, Carpentier A, Wanless IR, Hemming AW, Croxford R, Greig PD, Lilly LB, Heathcote JE, Levy GA, et al. Hepatitis C-related cirrhosis: a predictor of diabetes after liver transplantation. Hepatology. 2000;32(1):87\u201390.","journal-title":"Hepatology"},{"issue":"3","key":"1198_CR42","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1111\/j.1478-3231.2007.01630.x","volume":"28","author":"F Imazeki","year":"2008","unstructured":"Imazeki F, Yokosuka O, Fukai K, Kanda T, Kojima H, Saisho H. Prevalence of diabetes mellitus and insulin resistance in patients with chronic hepatitis C: comparison with hepatitis B virus-infected and hepatitis C virus-cleared patients. Liver Int. 2008;28(3):355\u201362.","journal-title":"Liver Int"},{"issue":"4","key":"1198_CR43","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.jinf.2004.06.001","volume":"50","author":"F Visnegarwala","year":"2005","unstructured":"Visnegarwala F, Chen L, Raghavan S, Tedaldi E. Prevalence of diabetes mellitus and dyslipidemia among antiretroviral naive patients co-infected with hepatitis C virus (HCV) and HIV-1 compared to patients without co-infection. J Infect. 2005;50(4):331\u20137.","journal-title":"J Infect"},{"key":"1198_CR44","unstructured":"Diabetes Statistics in Canada [http:\/\/www.diabetes.ca\/how-you-can-help\/advocate\/why-federal-leadership-is-essential\/diabetes-statistics-in-canada]"},{"key":"1198_CR45","unstructured":"Government of Canada, \u201cData Blog: Diabetes in Canada\u201d Health-Infobase. 2019. https:\/\/healthinfobase.canada.ca\/datalab\/diabetes-blog.html."},{"key":"1198_CR46","volume-title":"Edited by Services UDoHaH","author":"Centers for Disease Control and Prevention","year":"2011","unstructured":"Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, 2011. In: Edited by Services UDoHaH. Atlanta: Centers for Disease Control and Prevention; 2011."},{"issue":"10","key":"1198_CR47","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1139\/apnm-2018-0567","volume":"44","author":"Z Hosseini","year":"2019","unstructured":"Hosseini Z, Whiting SJ, Vatanparast H. Type 2 diabetes prevalence among Canadian adults - dietary habits and sociodemographic risk factors. Appl Physiol Nutr Metab. 2019;44(10):1099\u2013104.","journal-title":"Appl Physiol Nutr Metab"},{"issue":"6","key":"1198_CR48","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.2337\/db08-1651","volume":"58","author":"SI Tschen","year":"2009","unstructured":"Tschen SI, Dhawan S, Gurlo T, Bhushan A. Age-dependent decline in beta-cell proliferation restricts the capacity of beta-cell regeneration in mice. Diabetes. 2009;58(6):1312\u201320.","journal-title":"Diabetes"},{"key":"1198_CR49","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/1743-422X-8-367","volume":"8","author":"EI Elhawary","year":"2011","unstructured":"Elhawary EI, Mahmoud GF, El-Daly MA, Mekky FA, Esmat GG, Abdel-Hamid M. Association of HCV with diabetes mellitus: an Egyptian case-control study. Virol J. 2011;8:367.","journal-title":"Virol J"},{"issue":"2","key":"1198_CR50","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S0168-8278(01)00143-X","volume":"35","author":"JM Petit","year":"2001","unstructured":"Petit JM, Bour JB, Galland-Jos C, Minello A, Verges B, Guiguet M, Brun JM, Hillon P. Risk factors for diabetes mellitus and early insulin resistance in chronic hepatitis C. J Hepatol. 2001;35(2):279\u201383.","journal-title":"J Hepatol"},{"key":"1198_CR51","doi-asserted-by":"publisher","first-page":"S153","DOI":"10.1016\/j.dsx.2016.12.025","volume":"11 Suppl 1","author":"DE Banks","year":"2017","unstructured":"Banks DE, Bogler Y, Bhuket T, Liu B, Wong RJ. Significant disparities in risks of diabetes mellitus and metabolic syndrome among chronic hepatitis C virus patients in the U.S. Diabetes Metab Syndr. 2017;11 Suppl 1:S153\u20138.","journal-title":"Diabetes Metab Syndr"},{"issue":"2","key":"1198_CR52","first-page":"438","volume":"98","author":"PJ Thuluvath","year":"2003","unstructured":"Thuluvath PJ, John PR. Association between hepatitis C, diabetes mellitus, and race a case-control study. Am J Gastroenterol. 2003;98(2):438\u201341.","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"1198_CR53","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1053\/j.gastro.2007.11.010","volume":"134","author":"R Moucari","year":"2008","unstructured":"Moucari R, Asselah T, Cazals-Hatem D, Voitot H, Boyer N, Ripault MP, Sobesky R, Martinot-Peignoux M, Maylin S, Nicolas-Chanoine MH, et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level, and liver fibrosis. Gastroenterology. 2008;134(2):416\u201323.","journal-title":"Gastroenterology"},{"issue":"4","key":"1198_CR54","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1159\/000488985","volume":"27","author":"F Farshadpour","year":"2018","unstructured":"Farshadpour F, Taherkhani R, Ravanbod MR, Eghbali SS. Prevalence and Genotype Distribution of Hepatitis C Virus Infection among Patients with Type 2 Diabetes Mellitus. Med Princ Pract. 2018;27(4):308\u201316.","journal-title":"Med Princ Pract"},{"key":"1198_CR55","doi-asserted-by":"publisher","first-page":"539361","DOI":"10.1155\/2013\/539361","volume":"2013","author":"MS Memon","year":"2013","unstructured":"Memon MS, Arain ZI, Naz F, Zaki M, Kumar S, Burney AA. Prevalence of type 2 diabetes mellitus in hepatitis C virus infected population: a Southeast Asian study. J Diabetes Res. 2013;2013:539361.","journal-title":"J Diabetes Res"},{"issue":"4","key":"1198_CR56","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1016\/j.jiph.2011.05.004","volume":"4","author":"W Chehadeh","year":"2011","unstructured":"Chehadeh W, Kurien SS, Abdella N, Ben-Nakhi A, Al-Arouj M, Almuaili T, Al-Mutairi O, Al-Nakib W. Hepatitis C virus infection in a population with high incidence of type 2 diabetes: impact on diabetes complications. J Infect Public Health. 2011;4(4):200\u20136.","journal-title":"J Infect Public Health"},{"issue":"1","key":"1198_CR57","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1186\/s12889-020-09464-0","volume":"20","author":"CL Cooper","year":"2020","unstructured":"Cooper CL, Read D, Vachon ML, Conway B, Wong A, Ramji A, Borgia S, Tam E, Barrett L, Smyth D, et al. Hepatitis C virus infection characteristics and treatment outcomes in Canadian immigrants. BMC Public Health. 2020;20(1):1345.","journal-title":"BMC Public Health"},{"issue":"5","key":"1198_CR58","doi-asserted-by":"publisher","first-page":"720","DOI":"10.5604\/01.3001.0010.2714","volume":"16","author":"CL Cooper","year":"2017","unstructured":"Cooper CL, Thavorn K, Damian E, Corsi DJ. Hepatitis C Virus Infection Outcomes Among Immigrants to Canada: A Retrospective Cohort Analysis. Ann Hepatol. 2017;16(5):720\u20136.","journal-title":"Ann Hepatol"},{"issue":"2","key":"1198_CR59","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3138\/canlivj.1.2.004","volume":"1","author":"C Greenaway","year":"2018","unstructured":"Greenaway C, Makarenko I, Tanveer F, Janjua N. Addressing hepatitis C in the foreign-born population: A key to hepatitis C virus elimination in Canada. Canadian Liver Journal. 2018;1(2):34\u201350.","journal-title":"Canadian Liver Journal"},{"issue":"10","key":"1198_CR60","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1097\/QAD.0b013e32832bd7af","volume":"23","author":"AA Butt","year":"2009","unstructured":"Butt AA, McGinnis K, Rodriguez-Barradas MC, Crystal S, Simberkoff M, Goetz MB, Leaf D, Justice AC. Veterans Aging Cohort S: HIV infection and the risk of diabetes mellitus. AIDS. 2009;23(10):1227\u201334.","journal-title":"AIDS"},{"issue":"10225","key":"1198_CR61","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/S0140-6736(20)30045-3","volume":"395","author":"Collaboration GBDCKD","year":"2020","unstructured":"Collaboration GBDCKD. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2020;395(10225):709\u201333.","journal-title":"Lancet"},{"issue":"2","key":"1198_CR62","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1007\/s10620-015-3983-3","volume":"61","author":"HK Dyal","year":"2016","unstructured":"Dyal HK, Aguilar M, Bartos G, Holt EW, Bhuket T, Liu B, Cheung R, Wong RJ. Diabetes Mellitus Increases Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Virus Patients: A Systematic Review. Dig Dis Sci. 2016;61(2):636\u201345.","journal-title":"Dig Dis Sci"},{"issue":"3","key":"1198_CR63","doi-asserted-by":"publisher","first-page":"e2431","DOI":"10.1097\/MD.0000000000002431","volume":"95","author":"JC Hwang","year":"2016","unstructured":"Hwang JC, Jiang MY, Lu YH, Weng SF. Impact of HCV Infection on Diabetes Patients for the Risk of End-Stage Renal Failure. Medicine (Baltimore). 2016;95(3):e2431.","journal-title":"Medicine (Baltimore)"},{"issue":"4","key":"1198_CR64","first-page":"483","volume":"8","author":"VF Iovanescu","year":"2015","unstructured":"Iovanescu VF, Streba CT, Ionescu M, Constantinescu AF, Vere CC, Rogoveanu I, Mota E. Diabetes mellitus and renal involvement in chronic viral liver disease. J Med Life. 2015;8(4):483\u20137.","journal-title":"J Med Life"},{"issue":"8","key":"1198_CR65","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/j.1468-1293.2007.00499.x","volume":"8","author":"MK Jain","year":"2007","unstructured":"Jain MK, Aragaki C, Fischbach L, Gibson S, Arora R, May L, Vardhineni K, Lee WM. Hepatitis C is associated with type 2 diabetes mellitus in HIV-infected persons without traditional risk factors. HIV Med. 2007;8(8):491\u20137.","journal-title":"HIV Med"},{"issue":"2","key":"1198_CR66","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1002\/dmrr.1065","volume":"26","author":"S Ali","year":"2010","unstructured":"Ali S, Stone M, Skinner TC, Robertson N, Davies M, Khunti K. The association between depression and health-related quality of life in people with type 2 diabetes: a systematic literature review. Diabetes Metab Res Rev. 2010;26(2):75\u201389.","journal-title":"Diabetes Metab Res Rev"},{"issue":"11","key":"1198_CR67","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1016\/j.jdiacomp.2017.08.001","volume":"31","author":"CC Chima","year":"2017","unstructured":"Chima CC, Salemi JL, Wang M. Mejia de Grubb MC, Gonzalez SJ, Zoorob RJ: Multimorbidity is associated with increased rates of depression in patients hospitalized with diabetes mellitus in the United States. J Diabetes Complications. 2017;31(11):1571\u20139.","journal-title":"J Diabetes Complications"},{"issue":"5","key":"1198_CR68","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.pcd.2016.02.003","volume":"10","author":"C Cols-Sagarra","year":"2016","unstructured":"Cols-Sagarra C, Lopez-Simarro F, Alonso-Fernandez M, Mancera-Romero J, Perez-Unanua MP, Mediavilla-Bravo JJ, Barquilla-Garcia A, Miravet-Jimenez S. Work Group of Diabetes S: Prevalence of depression in patients with type 2 diabetes attended in primary care in Spain. Prim Care Diabetes. 2016;10(5):369\u201375.","journal-title":"Prim Care Diabetes"},{"issue":"Suppl","key":"1198_CR69","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1016\/S0165-0327(12)70004-6","volume":"142","author":"T Roy","year":"2012","unstructured":"Roy T, Lloyd CE. Epidemiology of depression and diabetes: a systematic review. J Affect Disord. 2012;142(Suppl):S8-21.","journal-title":"J Affect Disord"},{"issue":"9","key":"1198_CR70","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.3748\/wjg.v23.i9.1697","volume":"23","author":"AC Desbois","year":"2017","unstructured":"Desbois AC, Cacoub P. Diabetes mellitus, insulin resistance and hepatitis C virus infection: A contemporary review. World J Gastroenterol. 2017;23(9):1697\u2013711.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"1198_CR71","doi-asserted-by":"publisher","first-page":"9","DOI":"10.14218\/JCTH.2015.00001","volume":"3","author":"EJ Raff","year":"2015","unstructured":"Raff EJ, Kakati D, Bloomer JR, Shoreibah M, Rasheed K, Singal AK. Diabetes Mellitus Predicts Occurrence of Cirrhosis and Hepatocellular Cancer in Alcoholic Liver and Non-alcoholic Fatty Liver Diseases. J Clin Transl Hepatol. 2015;3(1):9\u201316.","journal-title":"J Clin Transl Hepatol"},{"issue":"6","key":"1198_CR72","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1053\/j.gastro.2003.08.032","volume":"125","author":"JM Hui","year":"2003","unstructured":"Hui JM, Sud A, Farrell GC, Bandara P, Byth K, Kench JG, McCaughan GW, George J. Insulin resistance is associated with chronic hepatitis C virus infection and fibrosis progression [corrected]. Gastroenterology. 2003;125(6):1695\u2013704.","journal-title":"Gastroenterology"},{"issue":"5","key":"1198_CR73","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1111\/j.1572-0241.2008.01813.x","volume":"103","author":"S Petta","year":"2008","unstructured":"Petta S, Camma C, Di Marco V, Alessi N, Cabibi D, Caldarella R, Licata A, Massenti F, Tarantino G, Marchesini G, et al. Insulin resistance and diabetes increase fibrosis in the liver of patients with genotype 1 HCV infection. Am J Gastroenterol. 2008;103(5):1136\u201344.","journal-title":"Am J Gastroenterol"},{"issue":"11","key":"1198_CR74","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.2169\/internalmedicine.50.4447","volume":"50","author":"H Miyaaki","year":"2011","unstructured":"Miyaaki H, Ichikawa T, Taura N, Miuma S, Shibata H, Isomoto H, Takeshima F, Nakao K. Predictive value of the fibrosis scores in patients with chronic hepatitis C associated with liver fibrosis and metabolic syndrome. Intern Med. 2011;50(11):1137\u201341.","journal-title":"Intern Med"},{"issue":"1","key":"1198_CR75","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1111\/liv.15056","volume":"42","author":"M Santos","year":"2022","unstructured":"Santos M, Protopopescu C, Delarocque-Astagneu E, Petrov-Sanchez V, Di Beo V, Larrey D, Baudoin M, Dorival C, Bureau M, Fontaine H, et al. Late presentation for HCV care: time to target people with diabetes and\/or hazardous alcohol use (ANRS CO22 HEPATHER cohort). Liver Int. 2022;42(1):38\u201349.","journal-title":"Liver Int"},{"issue":"Suppl 1","key":"1198_CR76","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/liv.13673","volume":"38","author":"T Asselah","year":"2018","unstructured":"Asselah T, Marcellin P, Schinazi RF. Treatment of hepatitis C virus infection with direct-acting antiviral agents: 100% cure? Liver Int. 2018;38(Suppl 1):7\u201313.","journal-title":"Liver Int"},{"key":"1198_CR77","doi-asserted-by":"publisher","first-page":"6150861","DOI":"10.1155\/2018\/6150861","volume":"2018","author":"S Drazilova","year":"2018","unstructured":"Drazilova S, Gazda J, Janicko M, Jarcuska P. Chronic Hepatitis C Association with Diabetes Mellitus and Cardiovascular Risk in the Era of DAA Therapy. Can J Gastroenterol Hepatol. 2018;2018:6150861.","journal-title":"Can J Gastroenterol Hepatol"},{"issue":"2","key":"1198_CR78","doi-asserted-by":"publisher","first-page":"215","DOI":"10.5604\/16652681.1231581","volume":"16","author":"JG Stine","year":"2017","unstructured":"Stine JG, Wynter JA, Niccum B, Kelly V, Caldwell SH, Shah NL. Effect of Treatment with Direct Acting Antiviral on Glycemic Control in Patients with Diabetes Mellitus and Chronic Hepatitis C. Ann Hepatol. 2017;16(2):215\u201320.","journal-title":"Ann Hepatol"},{"issue":"5","key":"1198_CR79","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1093\/eurpub\/ckn037","volume":"18","author":"P Virtanen","year":"2008","unstructured":"Virtanen P, Vahtera J, Broms U, Sillanmaki L, Kivimaki M, Koskenvuo M. Employment trajectory as determinant of change in health-related lifestyle: the prospective HeSSup study. Eur J Public Health. 2008;18(5):504\u20138.","journal-title":"Eur J Public Health"},{"issue":"1","key":"1198_CR80","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2471\/BLT.14.138149","volume":"93","author":"JB Nachega","year":"2015","unstructured":"Nachega JB, Uthman OA, Peltzer K, Richardson LA, Mills EJ, Amekudzi K, Ouedraogo A. Association between antiretroviral therapy adherence and employment status: systematic review and meta-analysis. Bull World Health Organ. 2015;93(1):29\u201341.","journal-title":"Bull World Health Organ"},{"issue":"28","key":"1198_CR81","doi-asserted-by":"publisher","first-page":"e4151","DOI":"10.1097\/MD.0000000000004151","volume":"95","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Stepanova M, Henry L, Nader F, Younossi Y, Hunt S. Adherence to treatment of chronic hepatitis C: from interferon containing regimens to interferon and ribavirin free regimens. Medicine (Baltimore). 2016;95(28):e4151.","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"1198_CR82","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/S0740-5472(01)00209-4","volume":"22","author":"S Lemke","year":"2002","unstructured":"Lemke S, Moos RH. Prognosis of older patients in mixed-age alcoholism treatment programs. J Subst Abuse Treat. 2002;22(1):33\u201343.","journal-title":"J Subst Abuse Treat"},{"issue":"8","key":"1198_CR83","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1080\/10826084.2020.1731546","volume":"55","author":"A Mejldal","year":"2020","unstructured":"Mejldal A, Andersen K, Bilberg R, Moller S, Nielsen AS. DSM-5 Latent Classes of Alcohol Users among Treatment Seeking Older Adults. Subst Use Misuse. 2020;55(8):1214\u201322.","journal-title":"Subst Use Misuse"},{"issue":"7","key":"1198_CR84","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1080\/08039488.2018.1522373","volume":"72","author":"ES Wieben","year":"2018","unstructured":"Wieben ES, Nielsen B, Nielsen AS, Andersen K. Elderly alcoholics compared to middle-aged alcoholics in outpatient treatment - 6-month follow-up. Nord J Psychiatry. 2018;72(7):506\u201311.","journal-title":"Nord J Psychiatry"},{"issue":"6","key":"1198_CR85","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1111\/liv.13629","volume":"38","author":"K Kozbial","year":"2018","unstructured":"Kozbial K, Moser S, Al-Zoairy R, Schwarzer R, Datz C, Stauber R, Laferl H, Strasser M, Beinhardt S, Stattermayer AF, et al. Follow-up of sustained virological responders with hepatitis C and advanced liver disease after interferon\/ribavirin-free treatment. Liver Int. 2018;38(6):1028\u201335.","journal-title":"Liver Int"},{"issue":"5","key":"1198_CR86","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1053\/j.gastro.2018.07.015","volume":"155","author":"P Nahon","year":"2018","unstructured":"Nahon P, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Ledinghen V, Ouzan D, et al. Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs. Gastroenterology. 2018;155(5):1436-1450 e1436.","journal-title":"Gastroenterology"},{"issue":"1","key":"1198_CR87","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/apt.14380","volume":"47","author":"E Ogawa","year":"2018","unstructured":"Ogawa E, Furusyo N, Nomura H, Dohmen K, Higashi N, Takahashi K, Kawano A, Azuma K, Satoh T, Nakamuta M, et al. Short-term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting anti-viral treatment. Aliment Pharmacol Ther. 2018;47(1):104\u201313.","journal-title":"Aliment Pharmacol Ther"},{"issue":"2","key":"1198_CR88","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jhep.2018.03.009","volume":"69","author":"A Romano","year":"2018","unstructured":"Romano A, Angeli P, Piovesan S, Noventa F, Anastassopoulos G, Chemello L, Cavalletto L, Gambato M, Russo FP, Burra P, et al. Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study. J Hepatol. 2018;69(2):345\u201352.","journal-title":"J Hepatol"},{"issue":"2","key":"1198_CR89","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1111\/apt.15296","volume":"50","author":"AJ Mecci","year":"2019","unstructured":"Mecci AJ, Kemos P, Leen C, Lawson A, Richardson P, Khakoo SI, Agarwal K, Mutimer D, Rosenberg WM, Foster GR, et al. The association between hepatocellular carcinoma and direct-acting anti-viral treatment in patients with decompensated cirrhosis. Aliment Pharmacol Ther. 2019;50(2):204\u201314.","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"1198_CR90","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.jhep.2017.07.025","volume":"67","author":"R Waziry","year":"2017","unstructured":"Waziry R, Hajarizadeh B, Grebely J, Amin J, Law M, Danta M, George J, Dore GJ. Hepatocellular carcinoma risk following direct-acting antiviral HCV therapy: A systematic review, meta-analyses, and meta-regression. J Hepatol. 2017;67(6):1204\u201312.","journal-title":"J Hepatol"},{"issue":"4","key":"1198_CR91","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1053\/j.gastro.2017.06.012","volume":"153","author":"F Kanwal","year":"2017","unstructured":"Kanwal F, Kramer J, Asch SM, Chayanupatkul M, Cao Y, El-Serag HB. Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents. Gastroenterology. 2017;153(4):996-1005 e1001.","journal-title":"Gastroenterology"},{"issue":"13","key":"1198_CR92","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.3748\/wjg.15.1537","volume":"15","author":"F Negro","year":"2009","unstructured":"Negro F, Alaei M. Hepatitis C virus and type 2 diabetes. World J Gastroenterol. 2009;15(13):1537\u201347.","journal-title":"World J Gastroenterol"},{"issue":"11","key":"1198_CR93","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.3390\/jcm10112509","volume":"10","author":"PY Su","year":"2021","unstructured":"Su PY, Chen YY, Yen HH, Huang SP, Liu IL, Zeng YH, Hsu YC, Siao FY. Strategy for the Micro-Elimination of Hepatitis C among Patients with Diabetes Mellitus-A Hospital-Based Experience. J Clin Med. 2021;10(11):2509.","journal-title":"J Clin Med"},{"issue":"1","key":"1198_CR94","doi-asserted-by":"publisher","first-page":"74","DOI":"10.4254\/wjh.v8.i1.74","volume":"8","author":"E Gonzalez-Reimers","year":"2016","unstructured":"Gonzalez-Reimers E, Lopez-Prieto J, Quintero-Platt G, Pelazas-Gonzalez R, Aleman-Valls MR, Perez-Hernandez O. de-la-Vega-Prieto MJ, Gomez-Rodriguez MA, Martin-Gonzalez C, Santolaria-Fernandez F: Adipokines, cytokines and body fat stores in hepatitis C virus liver steatosis. World J Hepatol. 2016;8(1):74\u201382.","journal-title":"World J Hepatol"},{"issue":"3","key":"1198_CR95","doi-asserted-by":"publisher","first-page":"734","DOI":"10.2337\/dc06-1539","volume":"30","author":"KG Tolman","year":"2007","unstructured":"Tolman KG, Fonseca V, Dalpiaz A, Tan MH. Spectrum of liver disease in type 2 diabetes and management of patients with diabetes and liver disease. Diabetes Care. 2007;30(3):734\u201343.","journal-title":"Diabetes Care"}],"container-title":["BMC Endocrine Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-022-01198-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12902-022-01198-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12902-022-01198-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,13]],"date-time":"2022-11-13T09:04:51Z","timestamp":1668330291000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcendocrdisord.biomedcentral.com\/articles\/10.1186\/s12902-022-01198-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,12]]},"references-count":95,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["1198"],"URL":"https:\/\/doi.org\/10.1186\/s12902-022-01198-x","relation":{},"ISSN":["1472-6823"],"issn-type":[{"value":"1472-6823","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,12]]},"assertion":[{"value":"8 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ottawa Hospital Research Institute\u2019s Ottawa Health Science Network Research Ethics Board study #2004-196. Research involving human data was performed in accordance with the Declaration of Helsinki. Informed consent to participate in study 2004-196 was obtained from all subjects.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"277"}}